OpenAI Ventures and Founders Fund Back Coherence Neuro for Brain Cancer Detection
OpenAI's venture arm joins Peter Thiel’s fund in a $45 million seed round for Coherence Neuro, signaling Big Tech’s deepening interest in neural data.
Key points
- OpenAI Ventures and Founders Fund invested in Coherence Neuro’s $45 million seed round.
- Coherence Neuro develops brain implants to detect cancer via electrical signals.
- This follows OpenAI’s January investment in Merge Labs for ultrasound-based brain-computer interfaces.
OpenAI’s venture capital arm and Peter Thiel’s Founders Fund have invested in Coherence Neuro, a startup developing brain implants for cancer detection. According to Wired, these investments are part of a $45 million seed funding round for the San Francisco-based company.
The funding reflects a broader trend of major technology firms betting on brain data. Coherence Neuro CEO Ben Woodington stated there is growing synergy between large AI laboratories and companies building brain-computer interface devices. He noted that AI companies align with the thesis that novel neural data sources hold significant value for training models.
Context and Background
Woodington described AI as a perfect use case for brain-computer interfaces because device developers generate massive datasets too large for human analysis. AI models can help read raw neural data and link it to specific actions, such as moving a computer cursor or producing synthesized speech.
This investment follows OpenAI’s January announcement of direct investment in Merge Labs, a brain-computer interface company co-founded by OpenAI CEO Sam Altman. Merge Labs emerged from stealth with $252 million in initial funding to pursue ultrasound technology capable of decoding information from the brain.
Who Is Affected
OpenAI stated at the time of the Merge Labs investment that it believed brain-computer interfaces would create a natural, human-centered way for anyone to interact with AI. Peter Thiel’s venture firm has also backed other neural technologies, including Elon Musk’s Neuralink and CTRL-labs, whose wristband translates neural signals from arm movements.
Unlike those companies, which often focus on restoring function for paralyzed individuals, Coherence Neuro focuses on decoding subtle electrical signals associated with brain tumors. The company aims to use AI models to identify these signals for medical diagnostics rather than general human-machine interaction.
What should you do?
Security professionals should monitor how AI companies handle sensitive neural data. Organizations involved in clinical trials should ensure robust data governance. Readers should watch for regulatory updates on brain-computer interface privacy.
What to do and how to stay safe: OpenAI
- Review data handling policies for any neural or biometric data your organization collects.
- Monitor regulatory developments regarding the privacy and security of brain-computer interface devices.
- Assess the security posture of third-party vendors providing AI-driven medical diagnostic tools.
- Ensure that patient data in clinical trials is encrypted and access is strictly controlled.
Step-by-step guide: Prompt Injection Warning Signs: How to Spot AI Manipulation
General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
Who is investing in Coherence Neuro?
OpenAI’s venture capital arm and Peter Thiel’s Founders Fund are investing in the company as part of a $45 million seed round.
What is Coherence Neuro developing?
The startup is developing brain implants and AI models to detect subtle electrical signals associated with brain tumors.
Has OpenAI invested in other brain-computer interface companies?
Yes, in January, OpenAI announced a direct investment in Merge Labs, which is developing ultrasound technology to decode brain information.
